Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus corticosteroids in pediatric chronic graft-versus-host disease
2018-003296-35Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), graft-versus-host disease (GVHD), cancer, sponsored by Novartis. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)graft-versus-host disease (GVHD)cancer
Beyond the preview
Go deeper on 2018-003296-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003296-35.